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INTRODUCTION 
 
MYASTHENIA GRAVIS 
 
EPIDEMIOLOGY 
 
Myasthenia gravis (MG) is an autoimmune disorder, most often caused by pathogenic 
antibodies (Abs) against the nicotinic acetylcholine receptor (AChR) at the 
neuromuscular junction (NMJ) [1]. The clinical syndrome was probably first 
described by Sir Samuel Wilks in 1877, in a woman initially thought to be suffering 
from hysteria presenting with generalized weakness, squint and dysphagia [2]. The 
term “myasthenia gravis” was coined by Friedrich Jolly in 1895. 
 
Although both incidence and prevalence have increased over time, MG is still a 
relatively rare disease. In 1984, the prevalence of MG in Norway was reported to be 
90 per million [3]. In 2007, the estimated prevalence of seropositive MG in Norway 
was 126.2 per million, with a yearly incidence of 7.2 per million for the period 1995 - 
2008. Taking into account a 15% stipulated portion of seronegative MG (SNMG) 
patients, the total MG prevalence was estimated to 145 per million [4]. Globally, a 
prevalence between 100 and 200 per million is found in most populations studied [5], 
while the reported incidence varies widely between 1.7 and 10.4 per million [1]. 
 
MG affects both sexes at all ages, but in women there is a peak in incidence during 
early adulthood (age < 40 years). The incidence has been reported to be equal in both 
sexes during puberty and at older ages [4], but other investigators report a higher 
incidence in men above age 50 [6]. There is evidence of MG being underdiagnosed in 
old age (> 80 years), and this has been attributed to a wider range of differential 
diagnoses in this age group, with symptoms being interpreted as stroke or motor 
neuron disease [7]. 
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CLINICAL FEATURES 
 
Being a disorder of the NMJ, MG causes purely motor symptoms. Classically, 
patients present with fatigueable muscle weakness, involving specific muscle groups 
or being generalized. Most affected individuals experience fluctuation of weakness 
from day to day, or even from hour to hour. Weakness and fatiguability worsens with 
activity and improves with rest [1, 5]. Ocular symptoms in the form of ptosis and/or 
diplopia are the commonest initial presentation, and are seen in 85 percent of MG 
patients. Of these, 80 percent eventually progress to generalized weakness, most 
within 1 year of disease onset [6]. Maximum severity is reached within 2 years in 
most patients.  
 
Prominent bulbar symptoms with dysarthria, dysphagia and facial weakness are more 
common in patients with antibodies against the muscle specific tyrosine kinase 
(MuSK) [8-9].  Respiratory muscles may be affected in MG, sometimes to a degree 
necessitating assisted ventilation. Such respiratory crises are more common in 
MuSK-positive MG. Of notion, weakness of ankle dorsiflexion is unusual in MG but 
not in congenital myasthenic syndromes (CMS), and so can be useful as a 
distinguishing feature [10]. 
 
 
MG SUBGROUPS 
 
MG is usually divided into subgroups according to age at onset, thymic pathology 
and antibody profile. This subdivision of patients is of clinical importance, as 
treatment decisions are based upon it. 
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OCULAR MG 
 
This subgroup is characterized by purely ocular symptoms, and comprises 17 percent 
of the total MG population. Some of these patients will eventually develop 
generalized disease, but if this does not occur within 2 years of disease onset, there is 
only a 10 percent risk that they will do so later on [6]. Ocular MG can affect all age 
groups. Abs to AChR are detected in 50 percent. Abs to MuSK are rare in ocular MG, 
but an association with Abs against acetylcholine esterase (AChE) have recently been 
found [11]. 
 
EARLY ONSET MG (EOMG) 
 
These patients have disease onset before 50 years of age, no thymoma is present and 
Abs against AChR are detectable. Titin Abs are found in 10 percent [12], but Abs 
against the ryanodine receptor (RyR) are very rare. The EOMG subgroup has a 
female:male ratio of about 2.5:1 [6]. Most affected individuals have thymic 
hyperplasia [13]. 
 
EOMG with thymic hyperplasia is associated with HLA-DR3 and B8 [14]. These 
alleles are part of the conserved 8.1 HLA haplotype, which also includes HLA-A1. 
The 8.1 HLA haplotype is also associated with several other autoimmune diseases, 
such as autoimmune thyroid disease, rheumatoid arthritis and systemic lupus 
erythematosus [14-15]. These diseases co-occur with markedly increased frequency 
in MG patients [16], suggestive of shared genetic susceptibility. A protective effect of 
HLA-DR7 has been reported for EOMG with thymic hyperplasia [17]. 
 
LATE ONSET MG (LOMG) 
 
Onset of disease is after 50 years of age, no thymoma is present. For LOMG there is 
no sex preponderance. All patients have Abs against AChR, about 60% have 
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additional titin Abs and 14% have also RyR Abs [12]. The course of the disease is 
often more severe in LOMG as compared to EOMG [18], particularly in patients with 
Abs against titin and RyR [19]. 
 
The thymus is usually normal or atrophic. There is an association with HLA-A3, B7, 
DR2 [20] and HLA-DR4 [21]. The presence of titin Abs is associated with HLA-
DR7, and these patients also have a low frequency of the HLA-DR3 allele [17]. 
 
THYMOMA MG 
 
Herman Hoppe, in 1892, speculated that a mass he found at autopsy near a large 
bronchus had caused auto-intoxication in a patient presenting with myasthenia [22]. 
About 10 percent of MG patients have a thymoma [6], while 30-50 percent of 
thymoma patients develop MG, which in these patients is considered a paraneoplastic 
disease [23]. In nearly all cases symptoms of MG precede the detection of the 
thymoma, which usually is otherwise asymptomatic [6, 24]. Thymoma MG occurs in 
all age groups, but with a peak onset around 50 years. Incidence is not influenced by 
gender [24], and the disease course is similar to LOMG [25-27]. 
 
Although associations with HLA-DQB1*0604 [28] and HLA-DRw15, Dw2 [21] 
have been reported in thymoma MG, this has not been reproducible. A protective 
effect of the 8.1 HLA haplotype has been suggested [29]. All thymoma MG patients 
have Abs against AChR. Titin and RyR Abs are found in 95 and 70 percent, 
respectively [12]. 
 
MuSK AB-POSITIVE MG 
 
In 2001, Hoch et al. described for the first time MuSK as a target for auto-Abs in MG 
patients without detectable Abs against AChR, and also demonstrated their functional 
effects on agrin-induced AChR clustering [30]. MuSK Abs have been detected in 
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only one patient with AChR Abs [31-32]. The proportion of MuSK Ab-positive 
patients among the AChR Ab-negative patients varies widely from 47% in Italy, 22% 
in the Netherlands, to 4% in Taiwan [8, 33-34]. In Norway, having a population of 
4.8 million, only three patients with MuSK Abs have been identified (unpublished 
data). 
 
An association with HLA-DR14 and DQ5 has been found in MuSK Ab-positive MG 
[35]. Standard therapy for MG is often less satisfactory in patients with MuSK Abs, 
but these patients usually respond well to additional therapy with mycophenolate, 
cyclosporine or cyclophosphamide [31]. 
 
MG WITH LOW-AFFINITY AChR ANTIBODIES 
 
The observation that MG patients without detectable Abs against AChR or MuSK 
resemble AChR Ab-positive MG both clinically and in the response to treatment [8-9, 
36-37], made it likely that apparent seronegativity was due to failure of current assays 
to detect the Abs.  
 
Indeed, using human embryonic kidney cells expressing clustered AChR, low-affinity 
Abs against AChR have been detected in 66 percent of MG patients who were 
negative for Abs against both AChR and MuSK using standard assays [38]. These 
low-affinity Abs are mainly of the IgG1 subclass and are able to activate 
complement, supporting their role in MG pathogenesis. 
 
SERONEGATIVE MG 
 
A proportion of MG patients remain without detectable Abs using both conventional 
and experimental assays, and these patients are referred to as seronegative. 
Nevertheless, there is substantial evidence that humoral factors are involved; the 
disease can be transferred vertically and to mice (both by plasma and immunoglobin 
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preparation) and patients improve after plasma exchange [39]. Both IgG and non-IgG 
(probably IgM) plasma factors may be important in causing the disease. Yet 
unidentified antigens on the postsynaptic membrane may be the target of pathogenic 
Abs. Also, some patients could be misdiagnosed due to the broad differential 
diagnosis of MG including Lambert-Eaton myasthenic syndrome, CMS, motor-
neuron disease, inflammatory neuropathies and myopathies. 
 
PATHOPHYSIOLOGY 
 
MG is prototypical both as an Ab-mediated autoimmune disease and as a disorder of 
neuromuscular transmission. In MG (and all other neuromuscular transmission 
disorders) the safety factor (SF) for neuromuscular transmission is compromised, 
eventually leading to transmission failure. The SF can be defined as 
 
SF = (EPP)/(EAP – EM) 
 
where EPP is the endplate potential amplitude, EAP is the threshold potential for 
initiating an action potential and EM is the resting membrane potential [40]. As is 
evident, EAP – EM equals the amount of depolarization needed to reach threshold. In 
MG, there is loss of both AChR and postsynaptic Na+ channels, compromising the SF 
by reducing the EPP and increasing EAP [41-42]. 
 
AChR ANTIBODIES 
 
The main antigen in MG is AChR located at the postsynaptic side of the NMJ, and 
AChR Abs are detected in about 85 percent of patients with generalised disease using 
routine assays [43]. Such Abs were described for the first time in 1976 by Lindstrøm 
et al. [44]. 
 
AChRs represent cation channels composed of 5 subunits. In muscle there are two 
subtypes of AChR, fetal and adult, which differ in one subunit as illustrated in fig. 1. 
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Figure 1: Composition of fetal and adult AChRs. From Kaminski (Ed.): Myasthenia 
gravis and related disorders [45]. 
 
Each AChR has two acetylcholine binding sites, located at the interface between α1 
and the adjacent subunit [46]. The cytoplasmic domain is linked to the cytoskeleton 
through interaction with rapsyn, this being essential for clustering of the receptors at 
the motor endplate [47]. Abs against AChR bind predominantly to a region on the 
extracellular tip of the α1 subunit known as the main immunogenic region (MIR) [48-
50], which is distant from the acetylcholine binding sites. Binding of Abs to the MIR 
is highly dependent on AChR being in its native conformation, suggesting that the 
MIR is a cluster of epitopes adjacent only in the native conformation.  
 
Abs against AChR impair neuromuscular transmission by 3 mechanisms: 
1. Antigenic modulation, which represents an increased rate of internalization 
and degradation of AChR due to cross-linking of the receptors by divalent 
Abs, thus reducing the number of AChR in the postsynaptic membrane [51-
52]. 
2. Complement-mediated lysis of the motor endplate, resulting in simplification 
of the folded pattern of the postsynaptic membrane with loss of both AChR 
and voltage-gated Na+ channels [42, 53-55]. As AChR loss due to antigenic 
modulation may be partly offset by an increased AChR synthesis [56-57], 
complement-mediated lysis is regarded as the most important mechanism for 
transmission failure in MG [58]. 
3. Reversible blockade of AChR by Abs directed against the acetylcholine 
binding sites [59-60]. 
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A correlation between AChR Ab titer and disease severity has not been found [44], 
but in an individual patient fluctuations in the clinical state are often accompanied by 
parallel changes in the Ab titer [61]. 
 
MuSK ANTIBODIES 
 
MuSK, by mediating agrin-induced clustering of AChR, is essential for development 
of the NMJ [62]. Abs against MuSK inhibit agrin-induced AChR clustering, 
indicating a possible effect also on maintenance of the NMJ, as MuSK is expressed at 
the mature NMJ [30]. Muscle weakness, electromyographical evidence of a 
neuromuscular transmission defect and reduced AChR clustering have been 
demonstrated in animal models with active MuSK immunization or passive transfer 
of IgG from MuSK Ab-positive MG patients [63-65]. 
 
MuSK Abs are predominantly IgG4, but they have also been shown to be of the IgG1 
subclass with the ability to activate complement [38]. Although the pathogenic 
mechanisms are still not clear, it seems that MuSK Ab-positive MG represents an 
immunologically distinct entity. 
 
OTHER ANTIBODIES 
 
A diversity of auto-Abs have been reported in MG, including Abs against 
myofibrillar proteins (myosin, actomyosin, tropomyosin, α-actinin and actin)  [66], 
the M1 muscarinic acetylcholine receptor [67],  β-adrenergic receptors [68] and non-
muscle antigens like interferon-α (INF-α) and interleukin-12 (IL-12) [69]. 
 
Titin is present in both skeletal and heart muscle, where it comprises the so-called 
third filament. It is the largest known protein to date, and produces passive force in 
striated muscle [70].  In 1990, Aarli et al. demonstrated that one group of non-AChR 
Abs found in the sera of thymoma MG patients was directed against titin [71]. 
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RyR is a calcium release channel of the sarcoplasmic reticulum and has an essential 
role in excitation-contraction coupling in striated muscle [72]. The RyR1 isoform 
predominates in skeletal muscle, while the RyR2 isoform is the most abundant in 
heart muscle. Abs against RyR bind to both of these isoforms, and it has been 
demonstrated that they inhibit calcium release in vitro [73]. As already described, 
RyR Abs are mostly found in thymoma MG [12]. 
 
Although both titin and RyR Abs are able to activate complement in vitro [74], there 
is no evidence that these Abs are pathogenic in vivo [75]. Since both titin and RyR 
are located intracellularly, generation of Abs against them may be secondary to 
muscle damage caused by AChR Abs, although the high specificity for thymoma MG 
makes this less likely. 
 
THYMIC INVOLVEMENT 
 
Abnormalities of the thymus, and especially thymic tumours, were found to be 
associated with MG over hundred years ago. Improvement of MG following removal 
of a non-tumorous thymus was observed for the first time in 1911 [22]. Since this, 
several lines of evidence support an important role for the thymus in MG 
pathogenesis. 
 
Muscle-like cells known as thymic myoid cells are found in the thymic medulla both 
normally and in MG. These cells express AChR but not MHC class II, making it 
unlikely that they themselves are able to present antigen (Ag) to CD4+ T cells [76]. 
However, professional antigen-presenting cells (APCs) could present AChR from 
myoid cells to AChR-specific CD4+ T cells. In the hyperplastic thymus of EOMG, 
perivascular infiltrates harbouring many APCs are frequent. Myoid cells are often 
located adjacent to, or within, these infiltrates [13]. 
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Germinal centers (GCs) with AChR-specific B cells undergoing clonal proliferation, 
somatic hypermutation and selection are also present in the thymic infiltrates, and 
follicular dendritic cells in these GCs present AChR on their dendritic processes [77].  
 
AChR Abs in MG are polyclonal in origin and belong to different IgG subclasses, 
implying that helper T cells are involved in the autoimmune response. Such AChR-
specific CD4+ T cells have been demonstrated in MG patients [78], and it has also 
been shown that they are more abundant in the thymus than in the blood [79-80]. 
However, AChR-specific T cells are also found in the blood of healthy individuals 
[81-82], so that in the normal situation these cells must be under tight regulatory 
control. Functional defects of thymic CD4+CD25+ regulatory T (Treg) cells have been 
reported in MG [83]. 
 
Medullary thymic epithelial cells are known to play an essential role in negative 
selection of self-reactive T cells through expression of virtually all self-Ags of the 
human body, a property known as promiscuous gene expression [84]. A single 
nucleotide polymorphism (SNP) in the promoter region of the CHRNA1 gene 
(encoding the α subunit of AChR) is associated with especially early onset of MG 
[85]. The MG-associated allele abrogated CHRNA1 promoter activity in thymic 
epithelial cells in vitro. Furthermore, both the CHRNA1 promoter variant and the 
autoimmune regulator gene (AIRE) was shown to modulate CHRNA1 mRNA levels. 
Downregulation of CHRNA1 expression in thymic epithelial cells could compromise 
negative selection of AChR-specific T cells. 
 
A two-step model for thymic autosenitization in MG has been proposed [86]. In the 
first step, AChR-specific T cells are primed by APCs and thymic epithelial cells. 
Secondly, myoid cells are attacked, eventually provoking local GC formation in the 
thymus leading to the production of high-affinity AChR Abs. 
 
In SNMG thymus, changes similar to those seen in EOMG are frequent, suggesting 
that these patients belong to the same etiologic group. In MuSK Ab-positive MG, 
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thymic changes are minimal, supportive of a different pathogenic mechanism in these 
patients [13]. 
 
PARANEOPLASTIC MG 
 
Thymomas are neoplasms arising from the thymic epithelium and are classified 
according to the World Health Organization histological classification system. During 
T cell development, CD4-CD8- T cell precursors migrate to the thymic cortex, where 
they develop into CD4+CD8+ T cells. These double-positive cells subsequently 
undergo positive and negative selection, before they differentiate into mature CD4+ or 
CD8+ T cells in the thymic medulla [87]. Only thymomas with a significant number 
of CD4+CD8+ T cells and also capable of exporting CD4+CD8- T cells to the 
periphery are associated with MG [23], indicating that these thymomas retain the 
ability to propagate the maturation of T cells. 
 
Thymoma epithelial cells express several epitopes cross-reactive with muscle 
proteins including AChR, titin and RyR [88-89], and their ability to present AChR 
peptides to T cells from patients with paraneoplastic MG has been demonstrated [90]. 
Both the expression of AIRE and the number of Treg cells are low in thymomas [91], 
and there is a selectively reduced export of Treg cells to the periphery [92]. MHC II 
expression is lower in thymomas than in the normal thymus. It might therefore be that 
T cells with high affinity T cell receptors, which normally are deleted during negative 
selection, instead survive [87]. In summary, it seems that mechanisms affecting both 
positive and negative selection are important in thymoma MG pathogenesis. 
 
In addition to MG, many other Ab-mediated paraneoplastic disorders are associated 
with thymoma, such as acquired neuromyotonia, limbic encephalitis and stiff person 
syndrome [93]; if the aforementioned mechanisms are responsible for thymoma-
associated autoimmunity, it seems reasonable that the autoimmune response is not 
always entirely restricted to AChR. 
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DIAGNOSIS 
 
Diagnostic tools in MG include clinical examination, pharmacological tests, 
electrophysiological measurements, tests for detection of auto-Abs and imaging. 
 
CLINICAL EXAMINATION 
 
Variation in the degree and distribution of muscle weakness on repeated 
examinations can be helpful in 
making the clinical diagnosis of 
MG. Deep tendon reflexes are 
typically normal, and skin sensation 
is intact. Differentiating between 
non-specific, generalized fatigue 
(which is common in the general 
population) and the objective 
fatigability and weakness of specific 
muscles characteristic of MG is 
pivotal. Affected muscles are tested, 
and the ptosis-test should be 
performed. Slurred speech due to 
tongue weakness may only be 
apparent after prolonged talking. 
Involvement of respiratory muscles 
should be thoroughly sought. 
 
After the diagnosis of MG is made 
the patient should be classified 
according to the Myasthenia Gravis 
Foundation of America (MGFA) 
clinical classification (table 1) [94]. The most severely affected muscles should be 
used to define the patient’s current clinical class. The maximum severity experienced 
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during the pre-treatment period should also be recorded and used as a reference point. 
 
PHARMACOLOGICAL TESTS 
 
Edrophonium chloride is an acetylcholinesterase inhibitor, prolonging the action of 
acetylcholine at the NMJ and thereby increasing the amplitude and duration of the 
EPP. It has a rapid onset (30 seconds) and short duration (5-10 minutes) of action. In 
the edrophonium test (also known as the Tensilon test), edrophonium chloride is 
administered intravenously and improvement in muscle strength is observed. 
Resolution of ptosis or improvement in the strength of a single extraocular muscle are 
considered the most reliable endpoints. This test has a diagnostic sensitivity of 70 – 
95 percent for generalized MG [95], but a positive response to edrophonium has also 
been reported in several other conditions and even in healthy controls. Although 
serious complications are rare, atropine should be readily available in case the patient 
develops severe bradycardia. 
 
A therapeutic trial with the orally administered acetylcholinesterase inhibitor 
pyridostigmine (Mestinon) for some days may also be of help in the diagnostic 
process [5]. 
 
ELECTROPHYSIOLOGICAL MEASUREMENTS 
 
In disorders of the NMJ, repetitive nerve stimulation (RNS) and single fiber 
electromyography (SFEMG) are used both to confirm the diagnosis, and also to 
exclude other defects of the motor unit. 
 
RNS causes depletion of ready releasable acetylcholine in the nerve terminal, leading 
to failure of neuromuscular transmission in a proportion of NMJs. Thus, fewer 
muscle fibers contribute to the compound muscle action potential (CMAP) resulting 
in a progressive decrease (decrement) in amplitude. A decrement of more than 10 
percent is usually considered abnormal. The characteristic finding in MG is a “U”-
shaped envelope pattern due to a decremental response with partial repair after the 
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third or fourth response of the train [95]. The sensitivity of RNS has been reported to 
be 53-100% for generalized MG and 10-29% for ocular MG, with specificities of 
97% and 94%, respectively [96-97]. To obtain maximal diagnostic yield several 
muscles should be tested, and in particular those that are clinically weak. 
 
SFEMG is the most sensitive test for defects in neuromuscular transmission, and can 
demonstrate abnormalities even in clinically unaffected muscles. The neuromuscular 
jitter is the variation in latency from nerve activation to muscle action potential, and 
is quantified by measuring variation in the time interval between the action potentials 
of two muscle fibers belonging to the same motor unit. The sensitivity of SFEMG 
have been reported to be 75-99% for generalized MG and 62-99% for ocular MG, 
with specificities of 96-98 % and 73-96%, respectively [96-97]. Studies of nerve 
conduction velocity and conventional electromyography should be done to exclude 
other primary disorders of nerve and muscle whenever SFEMG is abnormal [95]. 
 
DETECTION OF AUTO-ABs 
 
AChR Abs are routinely measured in a radioimmunoassay (RIA) with 125Iα-
bungarotoxin-labeled AChR as Ag [98]. Abs are detectable in 85 percent of 
generalized MG patients using this assay, and their presence verifies the diagnosis. 
Recently, a new assay for detection of AChR Abs has been developed [38]; this 
utilizes clustered AChR on the surface of transfected human embryonic kidney cells 
as Ag, and has the capacity to detect low-affinity Abs in a proportion of MG patients 
formerly negative for Abs to both AChR and MuSK. 
 
MuSK Abs are routinely measured in a RIA with 125I-MuSK as Ag, or in an enzyme-
linked immunosorbent assay (ELISA) with the extracellular domain of MuSK as Ag. 
A cell-based assay similar as that for AChR has also recently been developed [99]. 
Testing for MuSK Abs should be done in all patients negative for Abs against AChR 
[1]. 
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Titin Abs are detected in an ELISA with the titin fragment MGT-30 as Ag [100-101], 
and this assay is available for commercial use. RyR Abs are detected by western blot 
using crude sarcoplasmic reticulum as Ag [102]. In a patient positive for Abs to both 
titin and RyR the probability of a thymoma is 70 percent, and so these Abs can be 
used as serological markers for paraneoplastic MG [12]. 
 
IMAGING 
 
Investigation for a thymoma by radiographic examination of the chest should be done 
in all patients with a confirmed diagnosis of MG. Computed tomography (CT) has an 
overall sensitivity of 87.1% for detecting thymic pathology, the sensitivity for 
thymoma and thymic hyperplasia being 88.5-97.1% and 36-71.4%, respectively [103-
104]. As magnetic resonance imaging is equal or inferior to CT in the diagnosis of 
most anterior mediastinal tumors, including thymoma, CT should be the initial 
modality of choice [105]. 
 
TREATMENT 
 
Resemblance of MG with curare poisoning was noted by both Jolly and Herman 
Oppenheim. In 1934, Mary Broadfoot Walker successfully relieved the symptoms of 
MG with the curare-antidote physostigmine, in 1935 with oral neostigmine [106]. 
 
SYMPTOMATIC DRUG TREATMENT 
 
Orally administered acetylcholinesterase inhibitors (most often pyridostigmine) are 
the initial treatment in MG, and may also be used alone as long-term treatment in 
milder cases. These drugs are purely symptomatic. As the concentration of 
acetylcholine increases also at muscarinic synapses adverse effects related to this may 
occur, the common ones being gut hypermotility, increased sweating, excessive 
respiratory and gastrointestinal secretions and bradycardia [107]. 
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IMMUNOSUPPRESSIVE DRUG TREATMENT 
 
Immunosuppressive treatment aims at inducing and then maintaining remission. Oral 
corticosteroids induce remission or marked improvement in 70-80 percent of MG 
patients, and should be the first-line immunosuppressive treatment [107]. A 
temporary exacerbation of MG may occur 4-10 days after initiation of steroid 
treatment, and so the dose should initially be low and then gradually increased. After 
remission is induced, steroids should be tapered to the minimum effective dose due to 
the high risk of adverse effects. 
 
Azathioprine is a purine antimetabolite which interferes with T cell function. When 
long-term immunosuppressive treatment is needed, azathioprine should be started 
together with corticosteroids to allow tapering of the latter to the minimum dose 
[107]. The combination of these two drugs are both more effective and better 
tolerated than steroids alone [108]. The therapeutic response to azathioprine can be 
delayed for 4-12 months, with maximal effect occurring after 6-24 months. About 10 
percent of patients experience flu-like symptoms or gastrointestinal disturbances. 
Liver enzymes and blood cell counts should be monitored as hepatitis and cytopenias 
are possible adverse effects. 
 
Other immunosuppressive drugs for the treatment of MG include mycophenolate 
mofetil, ciclosporin, cyclophosphamide, tacrolimus and methotrexate. These drugs 
should be considered in patients unresponsive or intolerant to steroids and 
azathioprine [107]. The use of monoclonal Abs directed against lymphocyte subsets 
is a promising approach for the treatment of MG. Good clinical outcome has been 
reported both for anti-CD20 (rituximab, a B cell inhibitor) [109-112] and anti-CD4 (a 
T cell inhibitor) [113],  but more evidence is needed [107]. 
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PLASMA EXCHANGE AND INTRAVENOUS IMMUNOGLOBULIN 
 
Plasma exchange works by removing Abs from the patient’s serum. Improvement is 
seen within the first week, lasting 1-3 months. Several case-series have shown a 
beneficial effect in MG [114], and plasma exchange are recommended as a short-term 
treatment in severe cases and in preparation for surgery [107]. Intravenous 
immunoglobulin are equally effective as plasma exchange in MG exacerbations 
[115]. 
 
THYMECTOMY 
 
No randomized controlled trials evaluating the effect of thymectomy for non-
paraneoplastic MG have been performed, but a trial is in progress [116]. In 
paraneoplastic MG thymectomy is always indicated irrespective of MG severity, with 
the aim of treating the tumour [107]. 
 
EOMG patients with generalized disease and persistent symptoms despite the use of 
acetylcholinesterase inhibitors are usually considered for thymectomy early on in the 
disease course. In LOMG, thymectomy is only recommended for the minority of 
patients with a hyperplastic thymus resembling EOMG. LOMG patients with titin 
Abs usually do not improve after thymectomy [5]. Thymectomy is not performed in 
ocular MG, as no beneficial effect is seen in these patients compared to medical 
treatment only [117-118]. In MuSK Ab-positive MG remission rates are low 
following thymectomy [8, 119], which therefore is not usually performed. There is no 
general agreement regarding the role of thymectomy for SNMG [107], but a similar 
postoperative course as for seropositive MG has been reported [120-121]. Negative 
health effects of thymectomy have never been found [5]. 
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GENETICS OF MYASTHENIA GRAVIS 
 
Several lines of evidence demonstrate the key role of genetic factors in MG. Up to 4 
percent of patients’ family members develop MG themselves  [122]. There is an 
excess of other autoimmune diseases among family members of MG patients [14], as 
well as in affected individuals themselves [16]. The co-occurrence of multiple 
autoimmune diseases suggests shared susceptibility factors. Twin studies have shown 
the concordance of MG to be significantly higher in monozygotic as compared to 
dizygotic twins [123], strongly suggestive of a genetic predisposition. 
 
GENETIC LOCI ASSOCIATED WITH MG 
 
Several genetic loci, including both MHC and non-MHC genes, have been reported to 
be associated with MG (reviewed in [14]). Some of these will be described here. 
 
HLA 
 
The most reproducible genetic association in MG is the HLA-A1, B8, DR3 haplotype 
with EOMG with thymic hyperplasia. Several studies have shown that the 
predominant association is with the HLA-B8 allele [20, 124-126]. A susceptibility 
locus, MYAS1, has been mapped to a 1.2 Mb region comprising the distal MHC III 
and proximal MHC I, including TNFA and TNFB [126]. It has also been reported that 
HLA-DR7 confers a protective effect in EOMG with thymic hyperplasia [17], with 
significant peaks of negative association in the TNF gene cluster and the HLA-A 
locus [14]. 
 
For LOMG, associations with HLA-A3, B7, DR2 [20] and HLA-DR4 [21] have been 
reported. Also, titin Ab-positive patients have an association with HLA-DR7 [17]. 
Paraneoplastic MG is associated with HLA-A25, and for patients with a B2 thymoma 
HLA-A2 shows a protective effect [127]. A protective effect has also been suggested 
for the 8.1 HLA haplotype in paraneoplastic MG [29]. In MuSK Ab-positive patients, 
there is an association with HLA-DR14, DQ5 [35]. 
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FCGR 
 
The genes encoding Fc gamma receptors (FcγR) are clustered on the long arm of 
chromosome 1. Two studies have investigated whether functional polymorphisms in 
FCGR2A (encoding FcγRIIa), FCGR3A (encoding FcγRIIIa) and FCGR3B (encoding 
FcγRIIIb) are associated with MG; the first study reported a high frequency of the 
FcγRIIa 131H/H genotype in thymoma MG patients [128], while the second study 
found a high frequency of the FcγRIIa 131R/R genotype among MG patients, but  
with no difference between subgroups [129]. 
 
FcγRIIa belongs to the group of activating FcγRs [130], and is found on virtually all 
cells of the myeloid lineage. The variant containing a histidine at amino acid position 
131 (131H) has a higher affinity for IgG2 than the variant containing an arginine 
(131R) [131]. Because activating and inhibitory FcγRs usually are found co-
expressed on the cell surface and are co-engaged by the IgG ligand, the cellular 
response is determined by their activation ratio [130]. Thus, polymorphisms affecting 
receptor affinity may well modify immune responses. 
 
IL10 
 
IL10, the gene encoding interleukin-10 (IL-10), is located on the short arm of 
chromosome 1. The expression level of IL-10 in peripheral blood mononuclear cells 
(PBMCs) stimulated by Con A is related to three SNPs in the IL10 promoter [132]; 
G/A at position -1082, T/C at position -819 and A/C at position -592. They constitute 
three haplotypes (GCC, ATA, ACC), which in combination are associated with high 
(GCC/GCC), medium (GCC/ATA, GCC/ACC) or low (ATA/ATA, ATA/ACC, 
ACC/ACC) expression of IL-10. 
 
There are also two CA repeat microsatellites designated IL10.G and IL10.R located 
in the IL10 promoter [133]. MG patients with high titres of AChR Abs have an 
association to IL10.G allele 134, and MG patients with normal thymic histology have 
an association to IL10.R allele 112 [134]. 
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TNF 
 
TNFA (encoding tumour necrosis factor α, TNF-α) and TNFB (encoding TNF-β) are 
located in the MHC class III region, between the complement cluster and HLA-B. 
Two SNPs located in the promoter region of TNFA may influence transcription 
levels; -308G/A [135] and -238G/A [136]. The high expression variant TNFA -308A 
(designated TNFA*T2) is associated with HLA-A1, B8, DR3, while the low 
expression TNFA -308G allele (designated TNFA*T1) is associated with HLA-DR4 
and DR6 [137]. TNFB contains an NcoI diallelic restriction fragment length 
polymorphism in the first intron; the TNFB*1 allele correlates with increased 
transcription of TNF-β compared to the TNFB*2 allele [138]. 
 
Titin Ab-negative MG patients (including EOMG) have an increased frequency of the 
TNFA*T2 and TNFB*1 alleles, while titin Ab-positive MG patients (including 
paraneoplastic MG) have an increased homozygote frequency of TNFA*T1 and 
TNFB*2 [139]. 
 
The different genetic associations among MG subgroups, along with the observed 
clinical and pathophysiological heterogeneity, support that subgroups represent 
distinct etiological entities. 
 
CYTOKINES IN MYASTHENIA GRAVIS 
 
Cytokines interact with each other and with the cells of the immune system in a 
complex network, and their effects may be pleiotropic. In experimental autoimmune 
myasthenia gravis (EAMG) CD4+ T cells are necessary for development of the 
disease [140]. SCID mice grafted with blood lymphocytes from MG patients produce 
Abs against human AChR and develop myasthenic symptoms only if CD4+ T cells 
are included in the graft [141]. Therefore, investigations have focused on the role of 
cytokines involved in CD4+ T cell function. 
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The Th1 subset of CD4+ T cells secrete pro-inflammatory cytokines such as 
interferon-γ (INF-γ), IL-2 and TNF-β, and are involved in activation of APCs and 
cell-mediated immune responses. However, Th1 cells also promote growth and 
differentiation of B cells producing complement-fixing Abs both in humans and 
rodents [142]. Th2 cells can downregulate Th1 cells and activated APCs by secreting 
anti-inflammatory cytokines like IL-4, IL-5 and IL-10, and they also promote growth 
and differentiation of B cells producing Abs that do not fix complement [142]. Given 
the importance of complement-mediated damage both in MG [58] and EAMG [143], 
Th1 cells may have a crucial role in their pathogenesis.  
 
IL-12 is the major growth and differentiation factor for Th1 cells [142]. Several lines 
of evidence have demonstrated its importance in EAMG pathogenesis, including the 
increased propensity seen with exogenous administration of IL-12 [144], and the 
prevention seen with knock-out of IL-12 signalling [145]. Results regarding the 
principal Th1 effector cytokine, INF-γ, have been conflicting. Investigators have 
reported INF-γ knock-out mice both to have similar [146] and reduced [147] 
susceptibility to EAMG as compared to wild-type mice, while others have found such 
mice to be resistant to EAMG [148]. 
 
The Th2 cytokine IL-4 appears to have a protective effect against EAMG, as IL-4 
knock-outs develop more severe and persisting myasthenia than their wild-type 
littermates [149-150]. Conversely, other Th2 cytokines seem to facilitate EAMG; 
Both IL-5 and IL-6 knock-out mice develop myasthenia less frequent and with less 
severity [151-152]. Due to its anti-inflammatory activity, IL-10 has been regarded as 
a possible therapeutic option in autoimmune diseases. PBMCs from MG patients 
show increased in vitro spontaneous secretion of AChR Abs, but not of IL-10 [153], 
and decreased IL-10 mRNA expression in non-stimulated PBMCs from MG patients 
in vitro has been reported [154]. To the contrary, both transgenic mice expressing IL-
10 under control of the IL-2 promoter and mice given subcutaneous IL-10 have an 
increased susceptibility to EAMG [155-156]. The diverging results regarding the role 
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of IL-10 in MG may reflect both the methodological variation and the complex and 
pleiotropic effects of this cytokine. 
 
CONGENITAL MYASTHENIC SYNDROMES 
 
CMS are inherited, usually autosomal recessive disorders in which failure of 
neuromuscular transmission is caused by specific presynaptic, synaptic or 
postsynaptic mechanisms. Affected individuals commonly present within the first 
year of life [10]. A genetic diagnosis is established in about half of CMS patients, and 
80 percent of these are postsynaptic [157]. 
 
During formation of the NMJ, agrin released from the nerve terminal activates 
MuSK, which subsequently activates rapsyn (Receptor Associated Protein of the 
SYNapse), a 43 kDa membrane-associated cytoplasmic protein. Rapsyn interacts 
directly with AChR, inducing their clustering in the postsynaptic membrane [158]. 
Dok-7 (Downstream Of Kinase 7), a 55 kDa cytoplasmic protein, is an indispensible 
player in this process; Dok-7 interacts directly with the cytoplasmic region of MuSK, 
and regulates its localization, activation and responsiveness to agrin [159]. By largely 
unknown mechanisms, the NMJ matures during the early period of postnatal life into 
its adult three-dimensional structure with gutters and folds in the postsynaptic 
membrane [158]. 
 
It is important to emphasise that CMS, being genetic disorders, do not benefit from 
immunosuppressive treatment. It is therefore essential to distinguish these patients 
from those with autoimmune neuromuscular transmission disorders, so as to prevent 
the inappropriate use of immunosuppressive drugs, and eventually also thymectomy. 
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RAPSYN CMS 
 
Mutations in rapsyn (encoded by the RAPSN gene located on the short arm of 
chromosome 11) are responsible for 10 percent of all CMS cases [157]. Endplate 
studies from these patients revealed AChR and rapsyn deficiency, and a simplified 
morphology with loss of postsynaptic folding [160]. Depending on the specific 
mutation(s), the molecular mechanisms responsible for AChR deficiency in rapsyn 
CMS include reduction in rapsyn self-association, stability, co-localization with 
AChR, and reduced stability of AChR clusters [161]. 
 
The usual presentation of rapsyn CMS is at birth with hypotonia, multiple joint 
contractures (arthrogryposis multiplex congenita), bulbar dysfunction and the need 
for mechanical ventilation. During early childhood, most patients experience 
recurrent episodic crises with apnea precipitated by minor infections. Later, most 
patients have mild symptoms, although strabismus is present in the majority. Some 
affected individuals, however, present during late childhood or in adulthood with 
symptoms resembling autoimmune MG. Patients with rapsyn CMS have a positive 
response to cholinesterase inhibitors [162].  
 
Although several mutations in rapsyn have been identified, in most cases the N88K 
(c.264C>A) mutation is present on at least one allele [10]. This is probably due to a 
founder effect in people of Indo-European heritage [163]. All reported patients with 
late-onset rapsyn CMS have at least one copy of the N88K mutation, the vast 
majority being homozygous [164]. The dominance of this mutation makes screening 
for rapsyn CMS quick and simple. 
 
Cholinesterase inhibitors are regarded as standard pharmacotherapy, but 3,4-
diaminopyridine is an option. Some patients may benefit from a combination of the 
two [47]. 
 
 
 32 
Dok-7 CMS 
 
Mutations in DOK7, the gene encoding Dok-7, are increasingly recognized as a cause 
of postsynaptic CMS. In a recent French cohort of CMS patients, DOK7 mutations 
were found in 18 percent, superseded only by mutations in CHRNE (47%). In four of 
these patients SNMG was initially suggested [165]. NMJs are small and simplified 
[166-167], and denervation, reinnervation and formation of ectopic NMJs occur 
[165]. AChR density and function are almost normal [166], but AChE activity is 
reduced [165]. In addition, presynaptic changes can be observed [165]. 
 
Dok-7 CMS usually presents in early childhood, although it may also present with 
hypotonia at birth. In a minority of patients, the initial presentation is in early 
adulthood [165, 168]. A waddling gait and frequent falls are typical. Weakness 
predominantly affects proximal muscles of both the upper and lower extremities, 
giving rise to a limb-girdle phenotype. Respiratory difficulties are common, and 
crises necessitating invasive ventilation may occur. Ocular involvement, most often 
ptosis, is usually present. Fluctuations in muscle weakness dependent on exercise are 
experienced by most patients. The disease course is often progressive, with many 
patients developing spinal deformities. 
 
In the majority of patients with Dok-7 CMS, a common four basepair duplication is 
detected in exon 7. This c.1124_1127dupTGCC mutation has been detected at least 
heterozygously in all late-onset patients identified [165, 168]. The high frequency of 
this mutation makes screening for Dok-7 CMS feasible. 
 
The response to treatment with cholinesterase inhibitors and 3,4-diaminopyridine is 
usually poor, and these drugs may even worsen the patients clinical state. However, 
the edrophonium test is positive in some patients, and some also improve transiently 
on pyridostigmine treatment [165, 168]. Treatment with ephedrine may give 
substantial improvement [165, 169]. 
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AIMS OF THE STUDY 
I. To investigate whether functional polymorphisms in the IL-10 promoter 
associate with MG (paper I). 
II. To investigate whether specific combinations of allelic variants individually 
associated with MG synergize in predisposing to MG (paper II). 
III. To investigate whether late-onset CMS caused by rapsyn or Dok-7 mutations 
are frequently misdiagnosed as SNMG (paper III). 
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SUMMARY OF RESULTS 
 
IL10 PROMOTER POLYMORPHISMS IN MG 
 
Since IL-10 is important in MG pathogenesis and polymorphisms in the IL10 
promoter influence the expression level of IL-10, we analyzed the distribution of 
these polymorphisms in MG patients and controls to determine whether they 
influenced MG susceptibility. The study included 64 MG patients (26 with EOMG, 
20 with LOMG, 14 with thymoma MG and 4 in which subgroup had not yet been 
determined) and 87 blood donors as healthy controls. All patients and controls were 
Norwegian Caucasians. 
 
A 587-base pair (bp) fragment of the IL10 promoter containing the three biallelic 
polymorphisms located at position -592, -819 and -1082 was amplified by 
polymerase chain reaction (PCR) and subsequently bidirectionally sequenced. The 
distribution of IL10 genotypes is shown in table 2 and figure 2. 
 
Table 2 
 
We found a significantly higher frequency of the ACC/ACC genotype in MG patients 
when compared to controls (12.5% vs. 3.4%, P=.05). The thymoma MG subgroup 
also had a significantly higher frequency of the ACC/ACC genotype (21.4%) when 
compared to controls (P=.03), as had the LOMG patients (20%, P=.02). EOMG 
patients had an increased frequency of the ATA/ATA genotype when compared to 
controls (19.2% vs. 3.4%, P=.02). 
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MG patients had a significantly lower frequency of the ACC/ATA genotype when 
compared to controls (6.3% vs. 19.5%, P=.03). The subgroup of LOMG patients had 
a lower frequency of the ATA/GCC genotype (5.0%) when compared to the 
remaining MG patients (P=.006). 
 
 
 
 
 
 
 
 
Figure 2: IL10 genotype distribution in MG subgroups and controls. 
 
Titin Ab-status was known for 40 patients (62.5%), of which 20 were positive. Titin 
Ab-positive patients were similar to thymoma and LOMG patients with an increased 
frequency of the ACC/ACC genotype when compared to controls (20.0% vs. 3.4%, 
P=.02). The distribution of IL10 genotypes in relation to titin Ab-status is shown in 
figure 3. 
 
 
 
 
 
 
 
Figure 3: IL10 genotype distribution and the presence of titin Abs. 
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POLYGENIC DISEASE ASSOCIATIONS IN MG 
 
Most genetic associations in MG are rather weak, and MG is probably a polygenic 
disease. We therefore wanted to investigate whether allelic variants in several genes, 
individually associated with MG, synergize in MG predisposition. The study included 
47 patients with generalized MG (18 with EOMG, 19 with LOMG and 10 with 
thymoma MG) and 92 blood donors as healthy controls. All were Norwegian 
Caucasians, and none were related. 
 
Two polymorphisms in the TNFA promoter were analyzed; -308G/A and -238G/A. 
As mentioned in the introduction, the low expression variant -308G is designated 
TNFA*T1 and the high expression variant -308A is designated TNFA*T2. In TNFB 
we analyzed the NcoI diallelic restriction fragment length polymorphism located in 
the first intron. FCGR2A was analyzed for the biallelic 131H/R polymorphism. 
Finally, we analyzed the IL10 promoter polymorphisms located at position -592, -819 
and -1082. 
 
When comparing all MG patients with controls, MG patients had a higher frequency 
of the IL10 ACC/ACC genotype (P=.01). We found no significant differences for 
other allelic variants, alone or in combination, when comparing all MG patients with 
controls. 
 
Thymoma MG patients had a higher frequency of TNFB*2 (85.7% vs. 35.6%, P=.01) 
and FCGR2A 131H/H (55.6% vs. 22%, P=.05) when compared to controls, as shown 
in table 3. 55.6% (5 of 9 for which data was available) of thymoma MG patients had 
the 3 thymoma MG-related allelic variants TNFA*T1, TNFB*2 and FCGR2A 
131H/H, a combination which occurred in only 6.5% of controls (P=.001) and 2.9% 
(1 of 34 for which data was available) of non-thymoma MG patients (P=.001). The 
risk of having thymoma MG correlated with the number of thymoma MG-associated 
allelic variants, as shown in figure 4. 
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Table 3 
 
 
Figure 4 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Titin Ab-positive MG patients had a similar genetic profile as thymoma MG patients, 
with the combination of TNFA*T1, TNFB*2 and FCGR2A 131H/H being found in 
31.6%, compared to 6.5% of controls (P=.007) and none of the titin Ab-negative MG 
patients (P=.02), as shown in table 4. 
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Table 4 
 
EOMG patients had an increased frequency of TNFB*1 (40% vs. 7.8%, P=.01) and 
the IL10 ATA/ATA genotype (16.7% vs. 2%, P=.05). No combination of EOMG-
associated allelic variants showed a significant difference in distribution between 
EOMG patients and controls, and the occurrence of more than one EOMG-associated 
allelic variant was rare both in EOMG patients and in controls. 
RAPSYN AND Dok-7 CMS IN SNMG PATIENTS 
 
Since late-onset CMS caused by rapsyn or Dok-7 mutations can resemble 
autoimmune MG both clinically and electrophysiologically, we wanted to investigate 
the frequency of these disorders in the population of apparent SNMG patients. DNA 
from 76 patients diagnosed with SNMG at a neurology department in Norway was 
obtained from the biobank at the Department of Neurology, Oslo University Hospital, 
Kirkeveien. 37 blood donors participated as healthy controls. 
 
Exon 2 of RAPSN and exon 7 of DOK7 were amplified by PCR and subsequently 
bidirectionally sequenced. In patients heterozygous for the rapsyn N88K mutation, 
the promoter and remaining exons were sequenced looking for an additional 
mutation. 
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Among the 76 SNMG patients, we found one who was homozygous for the rapsyn 
N88K mutation, i.e. she had late-onset postsynaptic CMS (figure 5a). We also found 
two carriers of this mutation, one patient and one control (figure 5b). 
 
Figure 5: Sequences showing the rapsyn N88K (c.264C>A) mutation in the a) homozygous 
and b) heterozygous states. 
a) Homozygous N88K (A at base 65) 
 
 
 
 
 
 
b) Heterozygous N88K (C+A at base 69) 
 
 
 
 
 
 
Sequencing of the RAPSN promoter and the 7 remaining exons in the patient 
heterozygous for N88K revealed no additional mutation. 
 
We reviewed the clinical data of the patient found to have late-onset rapsyn CMS. 
Myasthenic symptoms presented for the first time in the post partum period at age 35 
years. She experienced muscle leg weakness and impaired swallowing, and later 
respiratory muscle weakness necessitating invasive ventilation. MG was suspected, 
and edrophonium and pyridostigmine had an alleviating effect. She was later 
thymectomized with no beneficial effect, and thymus histology was normal. 
 
Sequencing exon 7 of DOK7 revealed no mutations in SNMG patients or in the 
controls. 
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GENERAL DISCUSSION 
Investigating MG patients for IL10 promoter polymorphisms, we found an increased 
frequency of the ACC/ACC genotype in titin Ab-positive, LOMG and thymoma MG 
patients. This association could be related to the presence of titin Abs, given the high 
frequency of such Abs in LOMG and thymoma MG. The increased frequency of the 
ACC/ACC genotype in the total MG population when compared to controls results 
from the high frequency of this genotype in LOMG and thymoma MG. In EOMG 
patients, a higher frequency of the ATA/ATA genotype was found. 
 
Interestingly, both the ACC/ACC and ATA/ATA genotypes are associated with low 
expression of IL-10 [132]. As differences in LPS-induced IL-10 secretion are related 
to corresponding differences in mRNA production, rather than increased mRNA 
stability, transcription is implicated as the principal mechanism for variation in IL-10 
production [170]. Thus, the finding of low-producer IL10 genotypes in MG points to 
IL-10 as a factor of importance in MG pathogenesis. 
 
Our finding of low producer IL10 genotypes in MG is in line with previous 
observations regarding the role of Th1 cells in MG pathogenesis; IL-10 is a powerful 
inhibitor of proliferation and cytokine production in Th1 cells both via its down-
regulating effect on APCs and by a direct inhibitory effect on the Th1 cells and their 
IL-2 and TNF production [171]. As Th1 cells induce synthesis of complement-fixing 
Abs [142] and complement-mediated lysis of the muscle endplate is regarded as the 
most important pathogenic mechanism in MG [58], low levels of IL-10 could 
exaggerate the autoimmune response in MG. 
 
IL-10 has also direct effects on B cells, and these effects are dependent upon their 
activation state. In B cells stimulated in vitro, IL-10 exerts suppressive influence 
during the initial activation, whereas it promotes an active response following 
activation [172]. IL-10 also inhibits IL-2 production, and IL-2 is a crucial 
differentiation factor for B cells [173-174]. 
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That MG is associated with low-producer IL10 genotypes may also explain part of 
the response to treatment with glucocorticoids. The IL10 promoter contains a 
glucocorticoid response element motif [133, 175], and glucocorticoids up-regulate 
constitutive IL-10 production in human monocytes, measured at both protein and 
mRNA levels. This effect is abolished by the glucocorticoid receptor antagonist 
RU486 [176]. Glucocorticoids also increase IL-10 expression in PBMCs from 
multiple sclerosis patients with acute relapse [177]. An association between -1082 
A/A (low producer) IL10 genotype and steroid-dependency has been shown for 
ulcerative colitis and Crohns disease [178]. 
 
In paper II, the increased frequency of the IL10 ACC/ACC genotype in the total 
group of MG patients was confirmed. However, the study population in paper II was 
also included in paper I, and so this was not a replication in an independent 
population. The association with the ACC/ACC genotype was also confirmed for titin 
Ab-positive MG patients, as was the association with the ATA/ATA genotype for 
EOMG. We did not find an association of the ACC/ACC genotype with LOMG and 
thymoma MG. However, the number of patients was lower in paper II, and so this 
study might have been underpowered to detect these differences in genotype 
distribution. Given a frequency of 3.4% for the ACC/ACC genotype in controls and 
an odds ratio of 7.64, a sample size of 70 in each group would be needed to give a 
90% power of achieving 5% significance. Paper II also confirmed previously reported 
associations at the TNFA, TNFB and FCGR2A loci with MG subgroups [128, 139, 
179]. 
 
We found that the risk of having a thymoma in patients with MG correlated with the 
number of allelic variants individually associated with thymoma MG. This 
demonstrates that thymoma MG is a polygenic disorder. It remains to be determined 
whether the association primarily exists with the development of MG in the 
population of thymoma patients or with the development of the thymoma per se.  
 
 42 
The thymoma MG-associated allelic variants can be used as markers for the presence 
of a thymoma in the MG population, in which thymomas are much more common 
than in non-MG controls. However, a CT scan of the chest is thought to have a 
sensitivity of about 90-95 percent for detecting a thymoma [103-104]. In our study, 
all thymoma MG patients for whom records were available had preoperative findings 
on CT of the mediastinum indicative of a thymoma. 
 
The genetic profile of thymoma MG patients corresponds to a phenotype with low 
expression of TNF-α, TNF-β and IL-10, and with optimal interaction between 
FcγRIIa and IgG2 [131-132, 135, 138]. Abs to AChR are predominantly of the IgG1 
and IgG3 subclasses, but anti-AChR IgG2 has also been detected in MG sera [180]. 
IgG2 has been demonstrated to be an effective inducer of EAMG [181]. Although 
IgG subclasses do not directly correspond in rodents and humans, it may be that IgG2 
Abs are involved in the induction of MG. 
 
Expression of several muscle epitopes has been identified in thymomas [88-89, 182-
184] and there is strong evidence for an intra-thymoma immunization process against 
them in paraneoplastic MG [80, 90-91]. Given that this immunization process 
involves IgG2, IgG2-Ag complexes will bind efficiently to FcγRIIa on APCs. 
Presentation of Ag epitopes to Th cells will lead to a predominantly humoral immune 
response, due to low levels of TNF-α and TNF-β. Furthermore, low levels of IL-10 
will promote the Ag-presentation of APCs and the production of Th1-dependent 
complement-fixing Abs (figure 6). 
 
 43 
Figure 6: Production of complement-fixing Abs is dependent on Th1 cells, while Th2 cells 
induce the production of Abs that do not fix complement. From Conti-Fine, et al. (2008). 
"CD4+ T cells and cytokines in the pathogenesis of acquired myasthenia gravis." Ann N Y 
Acad Sci 1132: 193-209 [185]. 
 
Our data show that Titin Ab-positive MG patients have a genetic profile similar to 
thymoma MG. Nearly all patients with paraneoplastic MG are positive for titin Abs 
[12], and one might speculate as to whether non-thymoma MG patients positive for 
titin Abs have already rejected an occult thymoma. Titin Abs are found in about 60 
percent of LOMG, but in only 10 percent of EOMG patients. Paraneoplastic MG has 
a peak onset around 50 years of age [23]. 
 
In EOMG, more than one EOMG-associated allelic variant rarely occurred in an 
individual patient. This correlates with previous findings in these patients, where the 
main association have been with the ancestral 8.1 HLA haplotype, which includes the 
TNFA*T2 and TNFB*1 alleles. A susceptibility locus termed MYAS1 has been 
mapped between the distal MHC III and proximal MHC I [126]. This 1.2 Mb region 
notably includes the TNF gene cluster. Thus, both previous observations and our 
study suggest that EOMG is more closely linked to a specific gene at the MYAS1 
locus, rather than to a specific combination of the allelic variants tested by us. The 
TNFA*T2 and TNFB*1 alleles correlate with a high TNF production [135, 138], 
which may contribute to thymic GC formation [186]. 
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In paper III, we screened 76 SNMG patients for the common mutations N88K 
(c.264C>A) and c.1124_1127dupTGCC in RAPSN and DOK7, respectively. We 
found one patient homozygous for the rapsyn N88K mutation. The patient underwent 
a thymectomy which we now know could have been avoided. This underlines the 
importance of considering late-onset rapsyn CMS in patients diagnosed with SNMG. 
The patient had strabismus and experienced deterioration of muscle weakness during 
intercurrent febrile illness, both typical of rapsyn CMS [10, 187-188]. Increased 
awareness of rapsyn CMS in the differential diagnosis of SNMG is important in order 
to make the correct diagnosis. 
 
In addition, two carriers of the rapsyn N88K mutation were identified, one patient 
and one control. We calculated a carrier frequency of 1.8% (2 out of 112) for this 
mutation, which is similar to the frequency of 1.7% previously reported in 300 
controls [189]. The homozygote frequency (q2) for rapsyn N88K was estimated: 
 
 
 
This estimated homozygote frequency suggests that the number of N88K 
homozygotes in the Norwegian population (4.8 million) is about 380. However, such 
a high carrier frequency of the N88K mutation has not been found in other studies 
[160, 162, 190]. The estimated number of N88K homozygotes may therefore be too 
high. In the region served by Haukeland University Hospital, having a population of 
1 million, there are only 5 patients with a diagnosis of CMS (ICD: G70.2). This 
strongly suggests that CMS is underdiagnosed. This is also suggested by others [169], 
although there is no reliable epidemiological information to confirm this.  
 
It is tempting to speculate as to whether a proportion of sudden infant death syndrome 
(SIDS) cases represent undiagnosed CMS. Parents of SIDS victims frequently report 
that their baby had symptoms of minor infection during the immediate days before 
death, especially respiratory tract symptoms, but these infections are not believed to 
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be the cause of death [191]. Most patients with rapsyn CMS experience recurrent 
episodic crises with apnea precipitated by minor infections [162]. One study reported 
presynaptic CMS due to mutations in CHAT (encoding choline acetyltransferase) as 
the underlying cause of SIDS [192]. To our knowledge there have not been any 
investigations for postsynaptic CMS in cases of SIDS. It would be interesting to 
pursue this in the future. 
 
Screening for rapsyn CMS is greatly facilitated by the dominance of the N88K 
mutation. Although only one of 76 SNMG patients in our study had rapsyn CMS, we 
propose testing all SNMG patients for the N88K mutation before initiating 
immunosuppressive treatment, and before eventual thymectomy. This is justified by 
the significant adverse effects of unnecessary immunosuppressive treatment and the 
ease of screening for the N88K mutation. 
 
We did not find any SNMG patients with the DOK7 c.1124_1127dupTGCC 
mutation. DOK7 mutations were found in 18 percent of CMS patients in a recent 
French cohort [165]. Four of these patients had an initial diagnosis of SNMG; three 
had an apparent response to steroids, two to intravenous immunoglobulin, and two 
were thymectomized. Thus, one should be aware of the possibility of Dok-7 CMS in 
patients diagnosed with SNMG.  
 
The relatively recent discovery of DOK7 mutations makes it likely that these will be 
increasingly recognized as the molecular basis for limb-girdle myasthenia of 
unknown aetiology in the future. Due to the high frequency of the 
c.1124_1127dupTGCC mutation, screening for Dok-7 CMS is feasible. 
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METHODOLOGICAL CONSIDERATIONS 
 
INVESTIGATION OF GENETIC ASSOCIATIONS (PAPERS I AND II) 
 
Genetic association studies for rare disorders like MG are case-control studies based 
on the comparison of allele frequencies between affected individuals and unaffected 
controls. A statistically significant difference indicates association of the genetic 
variant with the disease. An association can arise for three principal reasons: 
1. The associated allele is causative for the disease. 
2. The associated allele is in linkage disequilibrium (LD) with the actual 
causative allele. 
3. A false-positive association. 
  
False-positive associations can occur due to a number of reasons; studies without 
correction of p-values for multiple hypothesis testing represent a widespread 
problem. Determining the appropriate level of statistical significance is of particular 
concern in genome-wide association studies, in which hundreds of thousands of SNPs 
are genotyped [193]. A false-positive association can also arise because of population 
stratification due to ethnic admixture. If the study population is mixed and the trait 
investigated is present at a higher frequency in one ethnic group, then any allele that 
also happens to be more frequent in that group will show a positive association with 
the trait [194-195]. Finally, different rates of genotyping error or success between 
cases and controls may lead to falsely different allele frequencies. 
 
All patients and controls included in papers I and II were Norwegian Caucasians. It is 
therefore unlikely that the observed associations are due to population stratification.  
 
In paper II, p-values were not corrected for multiple hypothesis testing. It can be 
argued that such correction, when analyzing small samples, increases the risk of 
making type II errors. An increased sample size and appropriate correction of p-
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values would be desirable. A multi-centre study would enable a larger sample size, 
but this would likely also increase genetic heterogeneity. Positive findings should 
always be confirmed in independent patient materials, this being especially important 
when small samples are examined and without correction for multiple comparisons. 
 
The TNFA and TNFB loci, located in the MHC class III region, are in LD with each 
other and with other loci in the MHC region on the short arm of chromosome 6. The 
FCGR2A and IL10 loci are located on the long and short arm of chromosome 1, 
respectively, and so they are not in LD with the other loci investigated in paper II. 
Therefore, the high frequency of multiple thymoma MG-associated alleles in 
individual thymoma MG patients is not merely due to LD between the investigated 
loci. 
 
A major problem in association studies has been a lack of reproducibility [196]. This 
can be attributed to three main causes: 
1. A false-positive association is correctly not replicated. This is probably 
responsible for a majority of non-reproducible associations [197]. 
2. A true association in one population is not true in a second population due to 
heterogeneity in their genetic or environmental background. If the investigated 
allele is not causal, but in LD with the causal allele, the extent of historical 
recombination may differ between populations. This will be reflected in the 
strength of association differing between the populations. 
3. A false-negative follow-up study. 
 
False-negative studies are most commonly due to an underpowered sample [195], and 
they are probably an important cause of the inconsistency seen in genetic association 
studies [197]. Due to the “winner’s curse” (a phenomenon explaining why the initial 
report describing an association nearly always overestimates the effect size [197]), 
follow-up studies should have a sample size large enough to detect a more modest 
effect size than initially reported. Similar to false-positive associations, false-negative 
results may also occur due to population admixture and technical errors. 
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If the sample size required in order to reach statistical significance is very large, i.e. 
the investigated association is weak, then the association will be of limited clinical 
relevance. However, such an association may still be important by pointing to the 
pathogenic mechanism involved. 
 
DETECTION OF GENETIC MUTATIONS (PAPER III)  
 
Bidirectional DNA sequencing is a sensitive method for the detection of point 
mutations, as well as small deletions and duplications. Deletions of whole exons, 
however, may easily be missed by this technique. Mutations in non-sequenced 
regions, e.g. intronic mutations affecting RNA splicing, will of course also be missed. 
To identify whole-exon deletions, quantitative PCR can be used. 
 
In paper III, we identified one SNMG patient who was heterozygous for the rapsyn 
N88K mutation. Bidirectional sequencing of the RAPSN promoter and remaining 
exons, including their flanking intronic sequences, did not reveal any additional 
mutations. We examined the sequences for all known SNPs, as heterozygosity for 
these would strongly indicate the presence of two disease-inducing alleles. However, 
these were all present at homozygosity. We cannot exclude the possibility of a whole-
exon deletion in this patient. 
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CONCLUSIONS 
 
The present study provides knowledge of genetic associations in MG. The study 
demonstrates how functional polymorphisms in the IL10 promoter are associated with 
subgroups of MG patients. The polymorphisms which associate with MG constitute 
low-producer IL10 haplotypes. This may be important in MG pathogenesis. Further 
studies investigating the role of IL-10 are needed to elucidate the complex role of this 
cytokine in MG. 
 
The risk of having a thymoma in patients with MG correlates with the number of 
allelic variants individually associated with thymoma MG. This demonstrates how 
thymoma MG is a polygenic disorder. The association could be with the development 
of MG among thymoma patients, or with the development of thymoma per se. 
Thymoma MG-associated allelic variants could be used as markers for the presence 
of a thymoma in the MG population. CT scan of the chest has, however, a higher 
sensitivity and specificity. 
 
In EOMG, the occurrence of more than one EOMG-associated allele in an individual 
patient is very rare. This suggests that EOMG is more closely linked to a specific 
gene at the MYAS1 locus, than to a specific combination of the allelic variants tested. 
 
Late-onset rapsyn CMS can be mistaken for SNMG even after a full examination by 
neurologists. However, the frequency of rapsyn CMS in our nationwide cohort of 
(apparent) SNMG patients is low. The carrier frequency of the rapsyn N88K mutation 
suggests that rapsyn CMS is underdiagnosed. There are no patients with late-onset 
Dok-7 CMS in our nationwide SNMG cohort. The DOK7 c.1124_1127dupTGCC 
mutation is not detected in any patients or controls. 
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ERRATA 
 
On pages 27 and 47 in the dissertation, IL10 is incorrectly described as being located 
on the short arm of chromosome 1. The correct location of IL10 is on the long arm of 
chromosome 1 (1q31-q32). 
 
Paper I 
Throughout the article, genotypes are referred to as haplotypes (e.g. ACC/ACC 
haplotype, which should be ACC/ACC genotype). Also, the IL10 gene is referred to 
as the IL-10 gene. 
 
Paper II 
Throughout the article, the IL10 gene is referred to as the IL-10 gene. 
 
In table 1, the P-value for the comparison of IL10 ACC/ACC genotype between 
thymoma MG patients and controls should be 0.17, not 1.7. All P-values comparing 
thymoma and non-thymoma MG patients should be in italics (column 6 of the table). 
 
In table 2, several P-values >0.05 are in boldface, while some P-values <0.05 are not; 
only P-values ≤0.05 should be in boldface. All P-values comparing titin Ab-positive 
and -negative MG patients should be in italics (column 6 of the table). 
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